Gilead Sciences CFO Andrew Dickinson: YEZTUGO Launch, Arcellx Acquisition, and Long-Cycle Growth

Gilead Sciences CFO Andrew Dickinson highlighted the company's strong pipeline, disciplined expenses, and growth in oncology sales to about $3 billion. He also discussed the acquisition of Arcellx, citing differentiated safety and strategic platform benefits for anito-cel, a BCMA cell therapy. Dickinson described the current period as "the beginning of a long cycle" with multiple product launches expected over the next year or two.